← Back to Search

Procedure

tDCS + Cognitive Training for Alzheimer's Disease

N/A
Recruiting
Research Sponsored by Baycrest
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months

Summary

This trial will test whether administering transcranial direct current stimulation (tDCS) at 4.0 mA, rather than the conventional 2mA, will produce more significant improvements in people with Alzheimer's Disease.

Who is the study for?
This trial is for individuals with mild to moderate Alzheimer's Disease who score between 18 and 25 on the MoCA cognitive test and can perform a memory task. It excludes those with stroke or brain injury history, metal implants/shunts in their body, or significant heart disease, alcoholism, or drug use.
What is being tested?
The study tests if transcranial direct current stimulation (tDCS) at a higher intensity of 4mA combined with cognitive training can be more effective than the conventional 2mA for improving symptoms in Alzheimer's patients.
What are the potential side effects?
Potential side effects of tDCS may include discomfort at the electrode site, itching, tingling during application, headache, fatigue, nausea. However these are generally mild and temporary.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
N-Back

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: 4mA StimulationExperimental Treatment1 Intervention
Group II: 2mA StimulationActive Control1 Intervention
Group III: SHAMPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

BrightFocus FoundationOTHER
4 Previous Clinical Trials
386 Total Patients Enrolled
BaycrestLead Sponsor
44 Previous Clinical Trials
6,423 Total Patients Enrolled

Media Library

tDCS (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05508841 — N/A
Alzheimer's Disease Research Study Groups: 4mA Stimulation, 2mA Stimulation, SHAM
Alzheimer's Disease Clinical Trial 2023: tDCS Highlights & Side Effects. Trial Name: NCT05508841 — N/A
tDCS (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05508841 — N/A
~14 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top